Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308964141> ?p ?o ?g. }
- W4308964141 endingPage "1155" @default.
- W4308964141 startingPage "1146" @default.
- W4308964141 abstract "The CORAL study highlighted the need to develop novel salvage regimens in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) previously treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Carfilzomib (CFZ) can overcome rituximab chemotherapy resistance in lymphoma preclinical models by targeting the ubiquitin-proteasome system. We conducted an investigator initiated, single-center, open-label, prospective phase 1 study evaluating the safety and efficacy of CFZ in combination with rituximab, ifosfamide, carboplatin, and etoposide (C-R-ICE) in high-dose chemotherapy with autologous stem cell transplant (HDC-ASCT) eligible patients with R/R DLBCL (NCT01959698). In the dose-escalation phase, 18 patients were enrolled at 6 dose levels with no dose-limiting toxicities noted. CFZ 45 mg/m2 was selected as the recommended dose for expansion. Eleven additional patients were enrolled in the dose-expansion phase. Overall response rate (ORR) was 66% (48% CR; 17% PR); 52% patients underwent HDC-ASCT. An ORR of 85% was observed in patients with nongerminal center B-cell-like (non-GCB) DLBCL compared with only 13% in those with GCB DLBCL. Median progression-free survival (PFS) was 15.2 months (5.1 months, not reached [NR]), and median overall survival (OS) was 22.6 months (6.8 months, NR). Patients with non-GCB subtype had a significantly longer PFS (NR vs 6.6 months; P = .0001) and OS (NR vs 6.6 months; P = .001) than those with GCB subtype. C-R-ICE is well tolerated in patients with R/R DLBCL with toxicities comparable to rituximab, ifosfamide, carboplatin, and etoposide therapy. Our data show that patients with non-GCB DLBCL benefit significantly from incorporating CFZ into second-line therapy and HDC-ASCT." @default.
- W4308964141 created "2022-11-20" @default.
- W4308964141 creator A5001862108 @default.
- W4308964141 creator A5008341315 @default.
- W4308964141 creator A5016042168 @default.
- W4308964141 creator A5017390861 @default.
- W4308964141 creator A5017589040 @default.
- W4308964141 creator A5019982069 @default.
- W4308964141 creator A5034919657 @default.
- W4308964141 creator A5037127160 @default.
- W4308964141 creator A5037345000 @default.
- W4308964141 creator A5041326751 @default.
- W4308964141 creator A5042987775 @default.
- W4308964141 creator A5043287179 @default.
- W4308964141 creator A5050643493 @default.
- W4308964141 creator A5062590009 @default.
- W4308964141 creator A5063296413 @default.
- W4308964141 creator A5064004889 @default.
- W4308964141 creator A5065111461 @default.
- W4308964141 creator A5066598802 @default.
- W4308964141 creator A5069146590 @default.
- W4308964141 creator A5083278460 @default.
- W4308964141 creator A5084501814 @default.
- W4308964141 creator A5087273890 @default.
- W4308964141 date "2023-03-30" @default.
- W4308964141 modified "2023-10-14" @default.
- W4308964141 title "Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL" @default.
- W4308964141 cites W1988703453 @default.
- W4308964141 cites W1997353354 @default.
- W4308964141 cites W2011046139 @default.
- W4308964141 cites W2028820057 @default.
- W4308964141 cites W2029421916 @default.
- W4308964141 cites W2043452076 @default.
- W4308964141 cites W2044306036 @default.
- W4308964141 cites W2072351874 @default.
- W4308964141 cites W2096301685 @default.
- W4308964141 cites W2111716055 @default.
- W4308964141 cites W2133201432 @default.
- W4308964141 cites W2133345449 @default.
- W4308964141 cites W2150587745 @default.
- W4308964141 cites W2565561569 @default.
- W4308964141 cites W2598700764 @default.
- W4308964141 cites W2786522183 @default.
- W4308964141 cites W2807205254 @default.
- W4308964141 cites W2921072067 @default.
- W4308964141 cites W2984927918 @default.
- W4308964141 cites W3108813332 @default.
- W4308964141 cites W3167371147 @default.
- W4308964141 cites W3212349863 @default.
- W4308964141 cites W3213065802 @default.
- W4308964141 cites W4200014243 @default.
- W4308964141 cites W4200201081 @default.
- W4308964141 cites W4200303223 @default.
- W4308964141 cites W4205736005 @default.
- W4308964141 doi "https://doi.org/10.1182/bloodadvances.2022008543" @default.
- W4308964141 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36375132" @default.
- W4308964141 hasPublicationYear "2023" @default.
- W4308964141 type Work @default.
- W4308964141 citedByCount "2" @default.
- W4308964141 countsByYear W43089641412023 @default.
- W4308964141 crossrefType "journal-article" @default.
- W4308964141 hasAuthorship W4308964141A5001862108 @default.
- W4308964141 hasAuthorship W4308964141A5008341315 @default.
- W4308964141 hasAuthorship W4308964141A5016042168 @default.
- W4308964141 hasAuthorship W4308964141A5017390861 @default.
- W4308964141 hasAuthorship W4308964141A5017589040 @default.
- W4308964141 hasAuthorship W4308964141A5019982069 @default.
- W4308964141 hasAuthorship W4308964141A5034919657 @default.
- W4308964141 hasAuthorship W4308964141A5037127160 @default.
- W4308964141 hasAuthorship W4308964141A5037345000 @default.
- W4308964141 hasAuthorship W4308964141A5041326751 @default.
- W4308964141 hasAuthorship W4308964141A5042987775 @default.
- W4308964141 hasAuthorship W4308964141A5043287179 @default.
- W4308964141 hasAuthorship W4308964141A5050643493 @default.
- W4308964141 hasAuthorship W4308964141A5062590009 @default.
- W4308964141 hasAuthorship W4308964141A5063296413 @default.
- W4308964141 hasAuthorship W4308964141A5064004889 @default.
- W4308964141 hasAuthorship W4308964141A5065111461 @default.
- W4308964141 hasAuthorship W4308964141A5066598802 @default.
- W4308964141 hasAuthorship W4308964141A5069146590 @default.
- W4308964141 hasAuthorship W4308964141A5083278460 @default.
- W4308964141 hasAuthorship W4308964141A5084501814 @default.
- W4308964141 hasAuthorship W4308964141A5087273890 @default.
- W4308964141 hasBestOaLocation W43089641411 @default.
- W4308964141 hasConcept C126322002 @default.
- W4308964141 hasConcept C126894567 @default.
- W4308964141 hasConcept C143998085 @default.
- W4308964141 hasConcept C2776063141 @default.
- W4308964141 hasConcept C2776364478 @default.
- W4308964141 hasConcept C2776694085 @default.
- W4308964141 hasConcept C2776755627 @default.
- W4308964141 hasConcept C2777506904 @default.
- W4308964141 hasConcept C2778119113 @default.
- W4308964141 hasConcept C2778239845 @default.
- W4308964141 hasConcept C2779338263 @default.
- W4308964141 hasConcept C2779429289 @default.
- W4308964141 hasConcept C2780108899 @default.
- W4308964141 hasConcept C2780653079 @default.